New Launch19 Oct 2026, 02:27 pm
Natco Pharma Launches Generic Carboplatin Injection in US
AI Summary
Natco Pharma Limited, through its U.S. subsidiary NATCO Pharma USA LLC, has announced the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market. This launch, in collaboration with Teyro Labs Pvt Ltd, aims to address a critical shortage of the product. Carboplatin Injection is used for the treatment of advanced ovarian carcinoma. The U.S. market for Carboplatin Injection had estimated sales of USD 27.8 million for the 12 months ending June 2026, according to industry sales data.
Key Highlights
- Natco Pharma launches generic Carboplatin Injection in the U.S.
- Product is a generic version of Paraplatin®.
- Aims to address a critical shortage in the U.S. market.
- US market sales for the product were estimated at USD 27.8 million.
Price Impact
More from NATCOPHARM